secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001193125-26-108292
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma reports Q4 net income of $1.6M on $21.9M collab revenue from ImmunoScape; cash $27.1M
--------------------------------------------------------------------------------

- Net income $1.585M ($0.01 EPS) in Q4 2025 vs net loss $9.496M in Q4 2024; full-year net loss $26.6M vs $40.7M.
- Collaboration revenue $21.9M in Q4 vs $1.6M; primarily from $9.5M upfront from ImmunoScape deal, with $5M due Nov 2026.
- R&D expenses $16.5M (up from $7.2M) on CUE-401 mfg and ImmunoScape-related costs; G&A $3.5M (down from $4.0M).
- Appointed Lucinda Warren CFO; raised $10.2M net in public offering; cash $27.1M at Dec 31, 2025.
- Advanced CUE-401 autoimmune drug toward IND; reported preclinical safety data; plans Virtual R&D Day.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/0001193125-26-108292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/cue-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-108292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer